2-Bromo-LSD

Synonyms: BOL-148; Bromolysergide
2-Bromo-LSD (BOL-148) 是一种能透过血脑屏障的 5-HT2A 部分激动剂和竞争性部分拮抗剂,在 5-HT2A 受体上同时发挥强效部分激动剂(针对 Gq 解离的 EC50 = 0.81 nM)和强效部分拮抗剂(针对 Gq 解离的 KB = 0.18 nM)的作用,对包括 5-HT2A 在内的多种胺能 GPCR 表现出部分激动作用,缺乏 5-HT2B 激动作用,可诱导树突生成和棘突生成,并逆转慢性应激的行为影响、增加小鼠的主动应对行为。
产品编号: MS-H73591 纯度: 97.26% CAS No.: 478-84-2 分子式: C20H24BrN3O 分子量: 402.33
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

2-Bromo-LSD (BOL-148) 是一种能透过血脑屏障的 5-HT2A 部分激动剂和竞争性部分拮抗剂,在 5-HT2A 受体上同时发挥强效部分激动剂(针对 Gq 解离的 EC50 = 0.81 nM)和强效部分拮抗剂(针对 Gq 解离的 KB = 0.18 nM)的作用,对包括 5-HT2A 在内的多种胺能 GPCR 表现出部分激动作用,缺乏 5-HT2B 激动作用,可诱导树突生成和棘突生成,并逆转慢性应激的行为影响、增加小鼠的主动应对行为。

生物实验数据

生物活性 2-Bromo-LSD (BOL-148) is a blood-brain barrier-permeable 5-HT2A partial agonist and competitive partial antagonist that acts at the 5-HT2A receptor as both a potent partial agonist (EC50 = 0.81 nM for Gq dissociation) and a potent partial antagonist (KB = 0.18 nM for Gq dissociation), exhibits partial agonism at multiple aminergic GPCRs including 5-HT2A, lacks 5-HT2B agonism, induces dendritogenesis and spinogenesis, and reverses the behavioral effects of chronic stress and increases active coping behavior in mice.
IC50 & Target

5-HT2A Receptor

0.81 nM (EC50)

5-HT2A Receptor

0.18 nM (Kb)

体外研究
(In Vitro)

2-Bromo-LSD 在 5-HT2A 受体上同时发挥强效部分激动剂 (针对 Gq 解离的 EC50 = 0.81 nM,Eₘₐₓ = 59.8%) 和强效部分拮抗剂 (针对 Gq 解离的 KB = 0.18 nM) 的作用。
2-Bromo-LSD 对 hERG 通道产生微弱的阻断作用 (IC50 = 31.6 μM)。
2-Bromo-LSD (1-10 μM; 3 h) 可促进原代大鼠皮质神经元的树突发生、树突棘密度。

体内研究
(In Vivo)

2-Bromo-LSD (0.125-4 mg/kg;腹腔注射) 可剂量依赖性地增加大鼠纹状体中 DOPA 的蓄积,在 2-4 mg/kg 剂量下达到最大效应,且该效应强于等摩尔浓度的 LSD;同时它可作为拮抗剂逆转 Apomorphine (MS-M00438) 诱导的 DOPA 蓄积减少,并阻断 LSD 对 GBL 刺激的 DOPA 蓄积的抑制作用。
2-Bromo-LSD (0.125-2.0 mg/kg;腹腔注射) 与 LSD 联合时,相较于相同剂量的单独使用 2-Bromo-LSD D-Tartrate,并未引起纹状体 DOPA 累积量的统计学显著变化。
2-Bromo-LSD (0.1-10 mg/kg;腹腔注射) 不会在雄性 C57BL/6J 小鼠中诱导致幻剂相关的甩头反应,但会呈剂量依赖性地阻断 DOI 诱导的甩头反应,在 3 mg/kg 剂量下抑制率达 76%。

Animal Model: Sprague-Dawley (male, 188-298 g)
Dosage: 0.125 mg/kg; 0.250 mg/kg; 0.5 mg/kg; 2 mg/kg; 4 mg/kg
Administration: i.p.; single dose; 30 minutes before sacrifice
Result: Increased striatal DOPA accumulation to 1386 ± 106 ng/g (n=6), significantly higher than saline control (1042 ± 77 ng/g, p<0.001) at 0.125 mg/kg.
Increased striatal DOPA accumulation to 1951 ± 380 ng/g (n=6), significantly higher than saline control (p<0.001) at 0.250 mg/kg.
Increased striatal DOPA accumulation to 1924 ± 131 ng/g (n=9), significantly higher than saline control (p<0.001) at 0.5 mg/kg; restored apomorphine (0.5 mg/kg)-reduced DOPA accumulation to 781 ± 28 ng/g from 472 ± 51 ng/g, and apomorphine (5 mg/kg)-reduced levels to 594 ± 42 ng/g from 249 ± 31 ng/g; showed no effect on reserpine-induced increased DOPA accumulation (2465 ± 243 ng/g vs.
2618 ± 136 ng/g, p=N.S.) and did not inhibit GBL-induced increased DOPA accumulation.
Increased striatal DOPA accumulation to 2630 ± 169 ng/g (n=6), significantly higher than saline control (p<0.001) at 2 mg/kg; produced larger maximum increase than equimolar LSD; restored apomorphine (0.5 mg/kg)-reduced DOPA accumulation to 2888 ± 111 ng/g from 472 ± 51 ng/g (levels not significantly different from BOL 2 mg/kg alone), and apomorphine (5 mg/kg)-reduced levels to 828 ± 190 ng/g from 249 ± 31 ng/g; showed no effect on haloperidol-induced or reserpine-induced increased DOPA accumulation, did not inhibit cerebral hemisection-induced increased DOPA accumulation on the sectioned side (1915 ± 215 ng/g vs.
2647 ± 400 ng/g, p=N.S.) but increased levels on the unsectioned side to 2058 ± 158 ng/g from 901 ± 232 ng/g (p<0.02); blocked LSD-induced inhibition of GBL-stimulated DOPA accumulation.
Significantly increased striatal DOPA accumulation compared to saline control and produced larger maximum increase than equimolar LSD at 4 mg/kg.
Animal Model: C57BL/6J (male and female, 7-8 weeks old)
Dosage: 0.3 mg/kg; 1.0 mg/kg; 3.0 mg/kg
Administration: three dose
Result: Increased time spent in the center of the OFT by 88.18 ± 18.89 seconds (female, 1.0 mg/kg) and showed a non-significant trend (female, 3.0 mg/kg).
Reduced FST immobility time by 35.18 ± 10.03 seconds (female, 1.0 mg/kg), 20.89 ± 8.249 seconds (male, 0.3 mg/kg), 27.27 ± 8.226 seconds (male, 1.0 mg/kg), and 31.36 ± 8.226 seconds (male, 3.0 mg/kg).
Showed a non-significant trend toward increased center time in the OFT (male, all doses).
Increased average PFC spine density compared to vehicle controls (both sexes, 1.0 mg/kg).
性状 固体
颜色 Off-white to light yellow

化学信息

分子量 402.33
分子式 C20H24BrN3O
CAS No. 478-84-2
别名 BOL-148; Bromolysergide

储存&溶解度

储存方式

-20°C, protect from light, stored under nitrogen

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础